Skip to main content
Regeneron10-Q: Product launch

FDA approved gene therapy Otarmeni and expanded Dupixent indications in Q1 2026

Source: Autobound Signal API · 93 signals tracked for Regeneron · updated

Get Regeneron's live signals in Claude or ChatGPT, or by API

AskWhat changed at Regeneron this week? Use Autobound signals for regeneron.com.

What happened

Regeneron secured FDA approval for Otarmeni (AAV-based gene therapy for OTOF-related hearing loss) and expanded approvals for Dupixent in AFRS and pediatric CSU. These clinical and commercial rollouts may require cold-chain logistics, gene therapy specialty distribution, and patient support software.

Source

SEC EDGARApr 29, 2026

Quarterly report (Form 10-Q)

Regeneron 10-Q for Quarter ended Mar 31, 2026

Filing excerpt

Otarmeni (lunsotogene parvec, formerly known as DB-OTO) AAV-based gene therapy Hearing loss due to variants of otoferlin ("OTOF") gene(c)(e)(m) (Phase 1/2) (pivotal study) Approved by FDA for hearing loss associated with variants in OTOF gene

sec.gov/Archives/edgar/data/872589/000087258926000016/regn-20260331.htmRead the full source

Other signals in this filing (4)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Product launch

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Mar 31, 2026
Fiscal year end
03/31
Filed
Apr 29, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Details

CIK
872589
Accession number
0000872589-26-000016
Timeframe
Current quarter
Quarter
Q1
Filing year
2026
Period end date
Mar 31, 2026
Why it matters
Go-to-market support
Signal category
Strategic

Topics and mentions

Technologies

  • AAV-based gene therapy

Regions named

  • U.S.
  • EU
  • Japan

Extraction

Confidence
High
Relevance
80%
Sentiment
Positive
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
productLaunch

Use this data

Get every 10-Q signal for Regeneron and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/da373278-2914-4392-a254-7607df2019f5 returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.

{
  "signal_id": "da373278-2914-4392-a254-7607df2019f5",
  "signal_type": "sec-10q",
  "signal_subtype": "productLaunch",
  "detected_at": "2026-11-09T06:24:49.567+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "detail": "Regeneron secured FDA approval for Otarmeni (AAV-based gene therapy for OTOF-related hearing loss) and expanded approvals for Dupixent in AFRS and pediatric CSU. These clinical and commercial rollouts may require cold-chain logistics, gene therapy specialty distribution, and patient support software.",
    "metrics": {
      "timeframe": "current_quarter"
    },
    "quarter": "Q1",
    "summary": "FDA approved gene therapy Otarmeni and expanded Dupixent indications in Q1 2026",
    "excerpts": "Otarmeni (lunsotogene parvec, formerly known as DB-OTO) AAV-based gene therapy Hearing loss due to variants of otoferlin (\"OTOF\") gene(c)(e)(m) (Phase 1/2) (pivotal study) Approved by FDA for hearing loss associated with variants in OTOF gene",
    "relevance": 0.8,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/regn-20260331.htm",
    "filing_date": "2026-04-29",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "03/31",
    "period_end_date": "2026-03-31",
    "sales_relevance": "Go-to-market support",
    "signal_category": "strategic",
    "regions_mentioned": [
      "U.S.",
      "EU",
      "Japan"
    ],
    "technologies_mentioned": [
      "AAV-based gene therapy"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.